425: Curaleaf Rebuts Aurora's Claims, Reaffirms Offer Value

Curaleaf Holdings issued a press release strongly refuting Aurora Cannabis's statements in its Directors' Circular, reiterating its offer and highlighting perceived financial and strategic weaknesses in Aurora's business.

Summary

• Curaleaf Holdings issued a press release on September 2, 2026, responding to Aurora Cannabis's recent circular.
• Curaleaf asserts its offer provides Aurora shareholders with a 45% premium and significant future upside in a larger, diversified cannabis platform.
• The company criticizes Aurora's financial management, citing substantial shareholder dilution through equity issuances totaling $398 million since September 2020 and ongoing dilution via an 'At the Market' program.
• Curaleaf points to Aurora's Board selling shares at prices below the current offer, suggesting a lack of belief in their own valuation arguments.
• Aurora's own guidance indicates a decline in fiscal 2027 revenue to near fiscal 2025 levels and a sharp decrease in adjusted EBITDA from fiscal 2026.
• Curaleaf highlights Aurora's negative operating cash flow in the June quarter, contrasting it with Curaleaf's $157 million in operating cash flow over the trailing twelve months.
• The company argues Aurora's continuous 'transformations' over six years represent its business model rather than a temporary phase, with significant transformation costs incurred annually.
• Curaleaf emphasizes its superior business fundamentals, including operating cash flow generation, strategic positioning for industry catalysts, and access to institutional debt markets.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the aggressive and critical tone used by Curaleaf in response to Aurora's circular, highlighting significant disagreements and perceived mismanagements by Aurora.

Positives

• Curaleaf's offer represents a 45% premium to Aurora's unaffected trading price, with an additional 110% premium excluding cash.
• The offer implies a CY2026E Adjusted EBITDA multiple of 12.0x for Aurora, which is over 68% higher than comparable Canadian peers.
• Curaleaf generated $157 million of operating cash flow in the trailing twelve months (LTM) period.
• Curaleaf generated $50 million in operating cash flow and $17 million in free cash flow during the first half of 2026, while investing $33 million in growth.
• Curaleaf successfully raised US$500 million of senior secured notes from institutional investors, indicating lender confidence.
• Curaleaf's Uncertain Tax Position (UTP) balance as a percentage of Total Enterprise Value (TEV) is 13%, which is among the lowest relative to the U.S. cannabis peer average of approximately 30%.
• Curaleaf generated US$145 million of operating cash flow over the LTM period ended June 30, 2026.
• Curaleaf's net debt (excluding UTP) represents approximately 25% of its total capitalization, below the peer average of 37%.

Negatives

• Aurora's own guidance forecasts fiscal 2027 revenue to return to approximately fiscal 2025 levels, with adjusted EBITDA expected to decline precipitously from fiscal 2026.
• Aurora's operating cash flow was negative C$4.4 million in the June quarter.
• Aurora has raised approximately US$398 million through dilutive share issuances since September 2020, resulting in approximately 31% shareholder dilution.
• Aurora's Board has sold shares through its ATM program at average prices of US$3.57 and US$3.09 per share within the last two quarters, prices materially below the Curaleaf offer.
• Aurora's management has consistently failed to properly integrate acquisitions, and auditors have reported ineffective controls over inventory and biological assets since FY2020.
• KPMG resigned as Aurora's auditor in April 2024.
• Canadian medical revenue has declined significantly, and Veterans Affairs Canada reimbursement rates have been reduced by almost 30%.
• German regulators have removed insurance reimbursement for Aurora's German business.

Risks

• Aurora's management's own guidance points to declining revenue and EBITDA, continued cash burn, and further shareholder dilution.
• Aurora's business model appears to be its continuous six-year transformation program, with significant transformation costs charged annually.
• Aurora's share price has hit all-time lows under the current management team.
• Auditors have reported ineffective controls over inventory and biological assets in each year since FY2020.
• Canadian medical revenue is expected to continue suffering due to reduced reimbursement rates by Veterans Affairs Canada.
• German regulators have removed insurance reimbursement, impacting Aurora's German business.
• Shareholders remain exposed to substantial additional equity dilution through existing ATM programs.
• The proposed transaction structure encourages Aurora shareholders to complete a transaction as soon as possible to lock in the exchange ratio and participate in potential upside with Curaleaf.

Future Outlook

Curaleaf's offer provides Aurora shareholders with the opportunity to participate in the upside of a substantially larger, more diversified cannabis platform. Aurora's own guidance suggests fiscal 2027 revenue returning to fiscal 2025 levels with a precipitous decline in adjusted EBITDA from fiscal 2026. Curaleaf projects its operating cash flow to grow to approximately US$165 million by FY27E, representing about 20% growth over FY25.

Management Comments

• "Aurora's continued refusal to engage in a meaningful price discussion regarding this transaction is disappointing and shows disregard for the interests of the Company's own shareholders."
• "Not once has there been a counteroffer presented to us, which shows managements' motives to preserve their own positions versus creating value for shareholders."
• "Rather than working constructively to evaluate a proposal that delivers immediate value and a substantial premium, Aurora's Board has chosen to rely on hollow arguments that are contradicted by its own actions."
• "Aurora's response sidesteps the fundamental question facing shareholders: if management's plan creates greater value than our offer, where is the evidence?"
• "Aurora's own guidance points to declining revenue and EBITDA, continued cash burn and further shareholder dilution."
• "By contrast, Curaleaf offers shareholders a 45% premium and immediate exposure to one of the largest and most diversified cannabis companies in the world."
• "We remain ready and willing to engage constructively with Aurora to discuss this offer at any point."
• "The question shareholders must ask the Board is simple - If Aurora's assets were worth substantially more apart than together why haven't those separation opportunities been pursued after six years of strategic reviews and repositioning efforts by the same management team?"

Industry Context

StockSavvy.ai notes that this filing represents a public relations battle in the context of a potential acquisition. Curaleaf is aggressively defending its offer and highlighting perceived weaknesses in Aurora's business and management to sway Aurora's shareholders. This tactic is common in hostile or contested takeover situations, aiming to undermine the target company's defense and create shareholder pressure for acceptance.

Comparison to Industry Standards

• Curaleaf's offer represents a 45% premium to Aurora's unaffected trading price, which is stated to be in the 63rd percentile of Canadian M&A premiums paid over the last 10 years.
• The implied CY2026E Adjusted EBITDA multiple for Aurora under Curaleaf's offer is 12.0x, which is stated to be more than 68% higher than comparable Canadian peers.
• Curaleaf's UTP balance as a percentage of TEV (13%) is noted as one of the lowest relative to the U.S. cannabis peer average of approximately 30%.
• Curaleaf's net debt (excluding UTP) represents ~25% of its total capitalization, which is below the peer average of 37%.
• Curaleaf's projected operating cash flow growth of ~20% by FY27E is significantly above the peer average of approximately 3%.
• Curaleaf's leverage ratio is expected to decrease from ~3.3x net debt to LTM adjusted EBITDA to 2.7x by FY2027E.
• Multi-Class Issuers on the TSX have historically outperformed the broader S&P/TSX Composite index with returns of 295% vs. 152% for the index.
• Curaleaf's relative share price performance has exceeded U.S. cannabis peers by ~42 percentage points and Aurora by ~57 percentage points since Boris Jordan's appointment as CEO on August 16, 2024.

Corporate Governance

Legal Proceedings

• Uncertain tax positions related to IRC section 280E are a well-understood phenomenon in the U.S. cannabis market and are captured as liabilities in valuations and trading multiples of U.S. Cannabis MSOs.

Stakeholder Impact

• Aurora shareholders are being offered a premium and participation in a larger, more diversified company, but also face potential risks associated with the integration and future performance of the combined entity.
• Curaleaf shareholders may benefit from the potential synergies and expanded market reach if the acquisition is successful.
• Employees of both companies may face uncertainty regarding roles and potential restructuring post-acquisition.
• Creditors of Aurora may see improved creditworthiness if Curaleaf's offer is accepted and the combined entity is financially stronger, but could also face risks if the integration is unsuccessful.

Next Steps

• Aurora shareholders are urged to read the offer documents carefully and in their entirety.
• Aurora shareholders are encouraged to visit Curaleaf's website and SEDAR+/EDGAR for additional information regarding the offer.
• Curaleaf remains ready and willing to engage constructively with Aurora to discuss the offer.

Key Dates

Recommendation

While Curaleaf presents a compelling case with a significant premium and highlights Aurora's operational and financial weaknesses, Aurora's Board has rejected the offer. The outcome remains uncertain, and Aurora shareholders should carefully evaluate both Curaleaf's offer and their Board's defense. A 'hold' recommendation reflects the need for further information and potential negotiation or shareholder action before committing to a buy or sell.

Keywords

cannabis, acquisition, takeover, offer, shareholder value, dilution, financial performance, management